Recent Posts
Archives
Kazia begins phase II study into paxalisib + a keto diet to treat brain cancer
![AdobeStock_261939312](https://www.irdepartment.com.au/site/irmblogpropertyfile/438/AdobeStock_261939312.jpg)
Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)
Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)